For research and educational purposes only. Not intended for human consumption.
Cartalax
Limited Research- •Khavinson bioregulator protocol data
- •Cartilage and connective tissue support research
- •Ki-67 proliferation marker modulation studies
AED Peptide | Cartilage & Connective Tissue Bioregulator
Overview
What is Cartalax?
Cartalax (AED peptide, T-31) is a synthetic tripeptide (Ala-Glu-Asp) developed by Professor Vladimir Khavinson as part of the bioregulatory peptide family. Originally isolated from kidney tissue and found in collagen, Cartalax supports cartilage, connective tissue, and cellular regeneration through modulation of proliferation markers and apoptosis pathways.
Key Benefits
Convenient oral administration, joint and connective tissue support, established safety profile in Russian clinical practice, used for degenerative conditions.
Mechanism of Action
Cartalax influences aging-related gene expression in stem cells, reduces pro-apoptotic p53 expression, and supports cellular regeneration in connective tissue and cartilage.
Molecular Information
Pharmacokinetics
Research Indications
Osteoarthritis Support
Russian studies show benefits for osteoarthritis and osteochondrosis.
Post-Fracture Recovery
Supports healing after bone and joint injuries.
Preventive Use
Used to prevent degenerative processes in elderly patients.
Research Protocols
Disclaimer: Khavinson bioregulator peptide. Take with meals as recommended by Russian manufacturers.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard Protocol | 100mcg (1 capsule) | Daily with meals | Oral |
| Intensive Support | 200mcg (2 capsules) | Daily with meals | Oral |
| Maintenance | 100mcg | Every other day | Oral |
Timing: With breakfast and/or dinner as recommended.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Oral capsules - no reconstitution needed
Take with meals
Swallow whole with water
Do not open or chew capsules
Store in cool, dry place
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Pharmaceutical packaging
Russian pharmaceutical products with holographic seals.
Correct capsule content
Each capsule should contain 0.1mg (100mcg).
Import verification
Ensure proper import documentation for authenticity.
What to Expect
- •Week 1-2: Establishing baseline, no significant changes
- •Week 3-4: Gradual improvement in joint comfort
- •Month 2: Noticeable mobility improvements
- •Month 3: Maximum therapeutic effect achieved
Side Effects & Safety
Side Effects
- •Well-tolerated in Russian clinical use
- •Take with meals for optimal tolerance
- •Can be combined with conventional treatments
- •No drug dependence reported
When to Stop
- •Adverse effects
- •No improvement after 3 months
- •As directed by provider
References
2 StudiesNeuronal Differentiation Study (2022)
Stem cells | 0.1 μg/ml | 7 days | Enhanced differentiation
Cartalax stimulated proliferation and neurogenic differentiation of stem cells.
Bone Marrow Stem Cell Study (2021)
MSCs | 10-100 nM | 14 days | Gene expression changes
Influenced aging-related gene expression in bone marrow mesenchymal stem cells.
Quick Start Guide
Research Disclaimer
Cartalax is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Cartalax must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Cartalax for any purpose. Consult qualified professionals for any research applications.